Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/12457
Title
Study of breast cancer incidence in patients of lymphangioleiomyomatosis.
Author(s)
Nuñez, Olivier ISCIII | Román, Antonio | Johnson, Simon R | Inoue, Yoshikazu | Hirose, Masaki | Casanova, Álvaro | de Garibay, Gorka Ruiz | Herranz, Carmen | Bueno-Moreno, Gema | Boni, Jacopo | Mateo, Francesca | Petit, Anna | Climent, Fina | Soler, Teresa | Vidal, August | Sánchez-Mut, José Vicente | Esteller, Manel | López, José Ignacio | García, Nadia | Gumà, Anna | Ortega, Raúl | Plà, María Jesús | Campos, Miriam | Ansótegui, Emilio | Molina-Molina, María | Valenzuela, Claudia | Ussetti, Piedad | Laporta, Rosalía | Ancochea, Julio | Xaubet, Antoni | Pujana, Miguel Angel | Pollan-Santamaria, Marina ISCIII
Date issued
2016-02
Citation
Breast Cancer Res Treat. 2016 Feb;156(1):195-201
Language
Inglés
Abstract
Molecular evidence has linked the pathophysiology of lymphangioleiomyomatosis (LAM) to that of metastatic breast cancer. Following on this observation, we assessed the association between LAM and subsequent breast cancer. An epidemiological study was carried out using three LAM country cohorts, from Japan, Spain, and the United Kingdom. The number of incident breast cancer cases observed in these cohorts was compared with the number expected on the basis of the country-specific incidence rates for the period 2000-2014. Immunohistochemical studies and exome sequence analysis were performed in two and one tumors, respectively. All cohorts revealed breast cancer standardized incidence ratios (SIRs) ≥ 2.25. The combined analysis of all cases or restricted to pre-menopausal age groups revealed significantly higher incidence of breast cancer: SIR = 2.81, 95 % confidence interval (CI) = 1.32-5.57, P = 0.009; and SIR = 4.88, 95 % CI = 2.29-9.99, P = 0.0007, respectively. Immunohistochemical analyses showed positivity for known markers of lung metastatic potential. This study suggests the existence of increased breast cancer risk among LAM patients. Prospective studies may be warranted to corroborate this result, which may be particularly relevant for pre-menopausal women with LAM.
Subject
MESH
Biomarkers, Tumor | Breast Neoplasms | Female | Humans | Incidence | Japan | Lymphangioleiomyomatosis | Neoplasm Metastasis | Sequence Analysis, DNA | Spain | United Kingdom
Online version
DOI
Collections
- Investigación > IIS > IDIBAPS - Instituto de Investigaciones Biomédicas August Pi i Sunyer (Cataluña) > IIS - Artículos
- Investigación > IIS > IDIBELL - Instituto de Investigación Biomédica de Bellvitge (Cataluña) > IIS - Artículos
- Investigación > IIS > IDIPAZ - Instituto de Investigación Sanitaria Hospital La Paz (Madrid) > IIS - Artículos
- Investigación > IIS > IIS-PRINCESA - Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (Madrid) > IIS - Artículos
- Investigación > IIS > IIS BIOCRUCES - Instituto de Investigación Sanitaria Biocruces Bizkaia (País Vasco) > IIS - Artículos
- Investigación > ISCIII > Centro Nacional de Epidemiología (CNE) > ISCIII - Artículos